GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Other Long-Term Liabilities

Gyre Therapeutics (Gyre Therapeutics) Other Long-Term Liabilities : $82.1 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Other Long-Term Liabilities?

Gyre Therapeutics's other long-term liabilities for the quarter that ended in Dec. 2023 was $82.1 Mil.

Gyre Therapeutics's quarterly other long-term liabilities increased from Dec. 2021 ($0.0 Mil) to Dec. 2022 ($0.1 Mil) and increased from Dec. 2022 ($0.1 Mil) to Dec. 2023 ($82.1 Mil).

Gyre Therapeutics's annual other long-term liabilities increased from Dec. 2021 ($0.0 Mil) to Dec. 2022 ($0.1 Mil) and increased from Dec. 2022 ($0.1 Mil) to Dec. 2023 ($82.1 Mil).

Gyre Therapeutics Other Long-Term Liabilities Historical Data

The historical data trend for Gyre Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Other Long-Term Liabilities Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Other Long-Term Liabilities
- - -

Gyre Therapeutics Semi-Annual Data
Dec21 Dec22 Dec23
Other Long-Term Liabilities - - -

Gyre Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Gyre Therapeutics Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics (Gyre Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Other Long-Term Liabilities
Comparable Companies
Traded in Other Exchanges
L9S:Germany
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Website
https://www.gyretx.com
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines

From GuruFocus

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

By PRNewswire • 12-15-2023